Baxter Files Section 337 Complaint on Surgical Hemostatic Matrix

Baxter filed on Feb. 28 a complaint with the International Trade Commission, alleging hemostatic products that infringe its patents are being imported by Johnson & Johnson, Ethicon, Ferrosan, and Packaging Coordinators, in violation of Section 337 of the tariff act. Baxter’s FLOSEAL is a “hemostatic matrix” that, when applied to a wound with a syringe, forms clots to stop bleeding during surgical procedures. According to Baxter, Ferrosan makes a similar product, SURGIFLO, that infringes Baxter’s patented technologies. The SURGIFLO is then imported by Johnson & Johnson and Ethicon, and. Packaging Coordinators turns the SURGIFLO into ready-to-use kits for Ferrosan and Ethicon. Baxter is requesting limited exclusion orders and cease and desist orders banning import and sale of infringing merchandise by Ferrosan, Johnson & Johnson, Ethicon, and Packaging Coordinators.